Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma

NCT03743298 is registered in ClinicalTrials.gov with Aivita Biomedical, Inc. as lead sponsor.

NCT NCT03743298
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03743298 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1B Trial of AV-MEL-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Antigens) With Anti-PD-1 Checkpoint Inhibitors in Metastatic Melanoma
Lead sponsor
Aivita Biomedical, Inc.
Phase
Phase 1
Overall status
Unknown status
Start date
April 21, 2021
Completion date
May 31, 2026
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic melanoma